Sanofi (France) Sues Eli Lilly and Company Over Challenge To Top Diabetes Drug Lantus

Published: Jan 31, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. firm's plans to produce a copycat version of Lantus. Lantus is the world's most prescribed insulin product, with annual worldwide sales of about $7 billion, but is set to lose patent protection in the United States, the world's largest pharmaceutical market, in February 2015. Sanofi's lawsuit, filed on Thursday, triggers an automatic 30-month stay of approval by the U.S. Food and Drug Administration (FDA), keeping Lilly's biosimilar drug off the U.S. market until mid-2016, more than a year later than its previously expected launch date.

Help employers find you! Check out all the jobs and post your resume.

Back to news